ArticleMaterials today. Bio2025
Allicin-loaded hydrogel enhances the viability of multiterritory perforator flap.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cracking the Sulfur Code: Garlic Bioactive Molecules as Multi-Target Blueprints for Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The multiterritory perforator flap has gained increasing clinical adoption in limb reconstruction and wound repair due to its procedural simplicity and distinct clinical advantages. Allicin, a multifunctional phytochemical renowned for its potent antioxidant properties, faces significant limitations due to rapid metabolic clearance, which substantially diminishes its therapeutic efficacy. Recent advances in hydrogel technology have highlighted their potential as advanced wound dressings, particularly through their capacity for sustained drug release. Our research synthesized HAMA-400K-Allicin (a hyaluronic acid methacryloyl hydrogel incorporating allicin), aiming to improve perforator flaps' survival rate by long-term oxidative stress alleviation. Characterization studies demonstrated that the synthesized hydrogel exhibits a densely crosslinked network architecture, robust tissue adhesion, and photosensitive properties. Notably, HAMA-400K-Allicin exhibited excellent biocompatibility and facilitated sustained allicin release for up to one week. Experimental validation revealed that both allicin and HAMA-400K-Allicin significantly improved perforator flap survival rates in rat models, with the hydrogel formulation demonstrating superior therapeutic outcomes. Mechanistic investigations further suggested that HAMA-400K-Allicin promotes flap survival through dual activation of the PI3K/AKT and HO-1/NRF2 signaling pathways. Ultimately, in a rat model, HAMA-400K-Allicin exhibited a robust effect in promoting perforator flap survival. In conclusion, this hydrogel system combines straightforward manufacturing processes with high clinical efficacy, positioning it as a promising solution for complex wound management scenarios.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.